Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
CD388 Injection
Influenza
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for CD388 Injection in Influenza are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07159763: Phase 3 trial, sponsor Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), drug CD388 Injection. Primary completion date 2027-06 (estimated).”